Malecare Prostate Cancer Support Group

Malecare

About Malecare

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT.  However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]

By |2017-10-19T10:48:30-04:00March 21st, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Cabazitaxel, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments
Read More

Tri-weekly Docetaxel Versus Bi-weekly Docetaxel as a Treatment for Advanced Castration Resistant Prostate Cancer: Quality of Life Analysis

Administering chemotherapy using docetaxel (taxotere or T) on a bi-weekly basis with prednisone improved progression free survival and overall survival when compared with the standard tri-weekly schedule for men with advanced castration resistant prostate cancer (CRPC) (Lancet Oncol. 2013;14:117-124). However, quality of life (QoL) differences have not been evaluated. In a trial to evaluate the [...]

By |2017-10-19T10:48:30-04:00March 20th, 2014|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|2 Comments
Read More

Identifying Men at Greatest Risk of Weight Gain from Androgen Deprivation Therapy

Androgen Deprivation Therapy (ADT) or Hormone Therapy (HT) to treat prostate cancer is a mainstay of therapy for men with recurrent or metastatic disease. There are many side effects associated with ADT including weight gain.   Weight gain, an adverse metabolic change, may contribute to cardiovascular comorbidity.  A better understanding of the risk factors for weight [...]

By |2017-10-19T10:48:30-04:00March 19th, 2014|Advanced Prostate Cancer, Uncategorized|0 Comments
Read More

Application for the FDA Approval of Xtandi in the Pre-Chemo State Has Finally been Submitted

The good news is that finally Astellas and Medivation have  submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI (enzalutamide) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. As of today XTANDI is currently only approved for [...]

By |2014-03-18T11:07:29-04:00March 18th, 2014|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, FDA, Uncategorized, Xtandi|0 Comments
Read More

Toxicity Analysis of Lymph Node Irradiation for Men with Prostate Cancer Treated with IMRT

The standard of treatment for men who have a localized recurrence in lymph nodes (LN) after surgery is intensity modulated radiation therapy (IMRT) as well as with men who have high-risk prostate cancer which includes cancer in both the prostate and seminal vesicles (SV).  As with all treatments the use of IMRT comes with many [...]

By |2017-10-19T10:48:30-04:00March 17th, 2014|adjuvant therapy, Advanced Prostate Cancer, Drugs & Treatments, Radiotherapy, Research, salvage therapy, Uncategorized, Understanding APC|1 Comment
Read More
Go to Top